Journal ArticleDOI
Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections: evaluation of 5 cases
Dino Sgarabotto,Riccardo Cusinato,Elena Narne,Fabio Scano,Matteo Zignol,Antonio Gambino,Anna Maria Cattelan,Francesco Meneghetti,Paolo Cadrobbi +8 more
TLDR
The experience with the combination of Synercid and vancomycin in 5 patients with severe infection caused by MRSA or methicillin-resistant coagulase-negative Staphylococcus is reported.Abstract:
Synercid (quinupristin/dalfopristin), the first semi-synthetic injectable streptogramin, is a promising alternative to glycopeptides against many Gram-positive multiresistant bacteria. Vancomycin is still considered an effective agent for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections but therapeutic failures with glycopeptides have been observed, even for the treatment of infections caused by S. aureus strains sensitive to vancomycin. Synercid, in combination with a glycopeptide, may address this problem without causing significant side effects due to the different toxicity patterns of the 2 antimicrobials. This study reports our experience with the combination of Synercid and vancomycin in 5 patients with severe infection caused by MRSA or methicillin-resistant coagulase-negative Staphylococcus.read more
Citations
More filters
Journal ArticleDOI
Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections
TL;DR: Vancomycin AUC24/MIC values predict time-related clinical and bacteriological outcomes for patients with lower respiratory tract infections caused by methicillin-resistant S. aureus by using data gathered from a therapeutic monitoring environment that observes failures in some cases.
Journal ArticleDOI
Quinupristin-Dalfopristin and Linezolid: Evidence and Opinion
TL;DR: Quinupristin-dalfopristin and linezolid demonstrate in vitro activity against a wide range of gram-positive bacteria, including many isolates resistant to earlier antimicrobials.
Journal ArticleDOI
Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.
TL;DR: Treatment options for MRSA including linezolid, quinupristin‐dalfopristin, daptomycin, and tigecycline are being reexplored in the setting of increasing concern over MRSA acquired in the community setting.
Journal ArticleDOI
Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?
TL;DR: The limitations of antibiotics currently available for the treatment of serious invasive MRSA infections are discussed and the existing literature that examines the potential role of combination therapy in these infections is reviewed.
Journal ArticleDOI
Diagnosis and management of Staphylococcus aureus bacteraemia.
TL;DR: All patients with SAB require careful clinical evaluation to exclude endocarditis and other metastatic foci, and most patients with features of complicated SAB, require prolonged intravenous antibiotic therapy, but a subgroup with good prognostic features may be suitable for shorter intravenous therapy.
References
More filters
Journal Article
Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999.
TL;DR: This report describes the fourth case of confirmed VISA from a patient in the United States, and increases the possibility that some strains of S. aureus will become fully resistant and that available antimicrobial agents will become ineffective for treating infections caused by such strains.
Journal ArticleDOI
Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
TL;DR: In patients with methicillin-resistant S. aureus or unresponsive MRSA infections, where few proven treatment options exist, quinupristin/dalfopristin should be considered as a treatment of choice for these seriously ill patients.
Journal ArticleDOI
Quinupristin-Dalfopristin: An Overview
TL;DR: Synercid (RP 59500), the first injectable streptogramin antibiotic, is composed of two semisynthetic pristinamycin derivatives, quinupristin and dalfopristin, which appears to have a role in treating severely ill patients with infections due to multiresistant gram‐positive pathogens.
Journal ArticleDOI
Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.
TL;DR: The drug is rapidly bactericidal against Gram-positive organisms (with the exception of enterococci) at concentrations similar to or within 4-fold of the MIC, and it has a long postantibiotic effect both in vitro and in vivo.
Journal ArticleDOI
In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus
TL;DR: Quinupristin/dalfopristin plus vancomycin was the most potent and reliable combination against both strains of S. aureus and ATCC 25923 and the MRSA in time-kill studies.